Interviews

Ariel Lopez-Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Cedric Pobel, MD, discusses the design and objectives of the phase 3 PEACE-1 trial for patients with de novo metastatic castration-sensitive prostate cancer.

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment strategies for TP53-mutant MDS and AML.

John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.

Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

Ghassan K. Abou-Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the treatment of patients with fibrolamellar carcinoma.

Ghassan K. Abou-Alfa, MD, discusses neratinib and its use as a monotherapy and in combination with immune checkpoint inhibitors and/or mTOR inhibitors in the SUMMIT trial.

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.

Martin Dreyling, MD, discusses the final follow-up results of the TRIANGLE study in mantle cell lymphoma.

Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, especially for patients who may not have easy access to PSMA PET scans.

Joseph Greer, PhD, discussed a study evaluating in-person vs telehealth modalities of early integrated palliative care for patients with advanced lung cancer.

Ryan Motte, PharmD, CSP, reviewed the global cancer burden among men and its projected trajectory to 2050, highlighting the role specialty pharmacies can play in combating this issue.

Sanjay K. Juneja, MD, discusses how artificial intelligence is transforming early cancer screening.

Sanjay K. Juneja, MD, discusses how artificial intelligence has evolved in 2024 to help improve early detection of cancer.

Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.

Chunhui Han, PhD, discusses the use of of Gallium 68 PSMA-11 in biology-guided radiotherapy and whether or not the radiotracer can improve the targeting and treatment of bony metastases in patients with prostate cancer.

In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.

Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.

Alexa Simon Meara, MD, discusses the importance of including a rheumatology approach to immunotherapy treatment for cancer.

Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer.

Paolo Ghia, MD, PhD, provides an overview of the CAPTIVATE trial, uncovering what investigators sought to evaluate.

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

Doris K. Hansen, MD, discussed a comprehensive analysis of pretreatment biomarkers associated with outcomes in patients receiving idecabtagene vicleucel therapy

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual Meeting.